JP2025502300A - ヘリカーゼプリマーゼ阻害剤の固体結晶形態及びその製造方法 - Google Patents
ヘリカーゼプリマーゼ阻害剤の固体結晶形態及びその製造方法 Download PDFInfo
- Publication number
- JP2025502300A JP2025502300A JP2024542125A JP2024542125A JP2025502300A JP 2025502300 A JP2025502300 A JP 2025502300A JP 2024542125 A JP2024542125 A JP 2024542125A JP 2024542125 A JP2024542125 A JP 2024542125A JP 2025502300 A JP2025502300 A JP 2025502300A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- hydrochloride
- degrees
- free base
- crystalline form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22151820.2 | 2022-01-17 | ||
| EP22151820 | 2022-01-17 | ||
| EP22170332.5 | 2022-04-27 | ||
| EP22170332 | 2022-04-27 | ||
| PCT/EP2023/050883 WO2023135303A1 (en) | 2022-01-17 | 2023-01-16 | Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025502300A true JP2025502300A (ja) | 2025-01-24 |
| JP2025502300A5 JP2025502300A5 (https=) | 2025-12-09 |
Family
ID=84982261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024542125A Pending JP2025502300A (ja) | 2022-01-17 | 2023-01-16 | ヘリカーゼプリマーゼ阻害剤の固体結晶形態及びその製造方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250115565A1 (https=) |
| EP (1) | EP4466255A1 (https=) |
| JP (1) | JP2025502300A (https=) |
| KR (1) | KR20240134979A (https=) |
| AU (1) | AU2023206628A1 (https=) |
| CA (1) | CA3246779A1 (https=) |
| CL (1) | CL2024002124A1 (https=) |
| IL (1) | IL314188A (https=) |
| MX (1) | MX2024008821A (https=) |
| PY (1) | PY2302301A (https=) |
| TW (1) | TW202337444A (https=) |
| UY (1) | UY40111A (https=) |
| WO (1) | WO2023135303A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL319024A (en) * | 2022-08-29 | 2025-04-01 | Assembly Biosciences Inc | Pharmaceutical preparations for the herpes virus |
| IL325911A (en) | 2023-07-17 | 2026-03-01 | Innovative Molecules Gmbh | Micronized crystalline hydrochloride salts of antiviral helicase-primase inhibitor compounds |
| WO2026078039A1 (en) | 2024-10-09 | 2026-04-16 | Innovative Molecules Gmbh | Oral administration forms of antiviral helicase-primase inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2000000109A (es) | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| DE10131128A1 (de) | 2001-06-28 | 2003-01-16 | Bayer Ag | Sekundäre Sulfonamide |
| GEP20207128B (en) | 2016-04-06 | 2020-07-10 | Molecules Gm Innovative | Aminothiazole derivatives useful as antiviral agents |
| MX2020003369A (es) | 2017-10-05 | 2020-07-29 | Innovative Molecules Gmbh | Enantiomeros de tiazoles sustituidos como compuestos antivirales. |
| TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
| KR20230131177A (ko) | 2020-10-29 | 2023-09-12 | 이노베이티브 몰리큘스 게엠베하 | 항바이러스 화합물로서 중수소화된 아미노티아졸 화합물 |
-
2023
- 2023-01-16 EP EP23700877.6A patent/EP4466255A1/en active Pending
- 2023-01-16 KR KR1020247027250A patent/KR20240134979A/ko active Pending
- 2023-01-16 JP JP2024542125A patent/JP2025502300A/ja active Pending
- 2023-01-16 TW TW112101829A patent/TW202337444A/zh unknown
- 2023-01-16 AU AU2023206628A patent/AU2023206628A1/en active Pending
- 2023-01-16 MX MX2024008821A patent/MX2024008821A/es unknown
- 2023-01-16 UY UY0001040111A patent/UY40111A/es unknown
- 2023-01-16 CA CA3246779A patent/CA3246779A1/en active Pending
- 2023-01-16 IL IL314188A patent/IL314188A/en unknown
- 2023-01-16 WO PCT/EP2023/050883 patent/WO2023135303A1/en not_active Ceased
- 2023-01-16 PY PY202302302301A patent/PY2302301A/es unknown
- 2023-01-16 US US18/729,411 patent/US20250115565A1/en active Pending
-
2024
- 2024-07-15 CL CL2024002124A patent/CL2024002124A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240134979A (ko) | 2024-09-10 |
| MX2024008821A (es) | 2024-07-29 |
| WO2023135303A1 (en) | 2023-07-20 |
| US20250115565A1 (en) | 2025-04-10 |
| PY2302301A (es) | 2023-10-31 |
| TW202337444A (zh) | 2023-10-01 |
| UY40111A (es) | 2023-08-15 |
| CA3246779A1 (en) | 2023-07-20 |
| IL314188A (en) | 2024-09-01 |
| AU2023206628A1 (en) | 2024-08-01 |
| EP4466255A1 (en) | 2024-11-27 |
| CL2024002124A1 (es) | 2024-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7174132B2 (ja) | オメカムチブメカルビルの塩及び塩を調製するプロセス | |
| JP2025502300A (ja) | ヘリカーゼプリマーゼ阻害剤の固体結晶形態及びその製造方法 | |
| JP7407171B2 (ja) | グリコシダーゼ阻害剤として有用なピペラジン誘導体のコハク酸付加塩及びフマル酸付加塩 | |
| TWI721947B (zh) | 抗病毒化合物的固態形式 | |
| JP2015522037A (ja) | ベムラフェニブコリン塩の固体形態 | |
| JP2023552274A (ja) | 抗ウイルス化合物としての重水素化アミノチアゾール化合物 | |
| KR101800140B1 (ko) | 벤조티아졸론 화합물 | |
| US10865198B2 (en) | Solid forms of cerdulatinib | |
| JP7252417B2 (ja) | Ｒｈｏキナーゼ阻害剤としてのベンゾピラゾール化合物の塩形、結晶形及びその製造方法 | |
| CN114075169B (zh) | 奥希替尼药用共晶体及其制备方法 | |
| CN121532378A (zh) | 抗病毒解旋酶-引发酶抑制剂化合物的微粉化结晶盐酸盐 | |
| CN114728982A (zh) | 固体形式的s1p-受体调节剂 | |
| TWI333856B (en) | Crystals of taxane and process for their production | |
| CN118556045A (zh) | 解旋酶-引发酶抑制剂的固体结晶形式及其制备方法 | |
| EA052003B1 (ru) | Твердые кристаллические формы ингибиторов геликазы-примазы и способ их получения | |
| EP3481801B1 (en) | Indoline derivatives and method for using and producing the same | |
| JP2025528904A (ja) | Ｔｙｋ２阻害剤およびその使用 | |
| HK40110051A (zh) | 解旋酶-引发酶抑制剂的固体结晶形式及其制备方法 | |
| JP7456641B2 (ja) | Ｐｅｔ放射性トレーサーとしての［１８ｆ］標識ベンゾチアゾール誘導体 | |
| US20250304635A1 (en) | Birinapant polymorph h | |
| JP2021533111A (ja) | Ｌｔａ４ｈ阻害剤の結晶形態 | |
| EP4610257A1 (en) | Crystal form of isoquinolinone compound and preparation method therefor | |
| AU2011346746A1 (en) | Polymorphs of 3-chloro-4[(2R)-2 | |
| CN108117570A (zh) | 一种替诺福韦艾拉酚胺半富马酸盐的结晶及其制备方法 | |
| WO2026017041A1 (zh) | 一种吡唑并喹唑啉类化合物及其盐型和晶型 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251128 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251128 |